FDA approved Penpulimab-kcqx for Non-Keratinizing Nasopharyngeal CarcinomaFDA approved new drug Penpulimab-kcqx for a type of nasopharyngeal cancer.

Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody. It binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Penpulimab-kcqx is indicated for: - In combination with either cisplatin or carboplatin and gemcitabine, for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). - As a single agent, for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

- For combination therapy: 200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity, for a maximum of 24 months. Administer penpulimab-kcqx first, then gemcitabine, then cisplatin or carboplatin. Recommended chemotherapy doses: gemcitabine 1000 mg/m² IV every 3 weeks for 6 cycles; cisplatin 80 mg/m² IV or carboplatin AUC 5 IV every 3 weeks for 6 cycles. - For single-agent use: 200 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity, for a maximum of 24 months. - Dilute prior to administration. - No dose reduction for penpulimab-kcqx is recommended. Withhold for severe (Grade 3) immune-mediated adverse reactions; permanently discontinue for life-threatening (Grade 4) immune-mediated reactions, recurrent severe Grade 3 reactions requiring systemic immunosuppression, or inability to reduce corticosteroid dose to ≤10 mg prednisone equivalent per day within 12 weeks.

Trial data not available in label.

- Immune-mediated adverse reactions: including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, exfoliative dermatologic conditions, myocarditis, and neurological toxicities. Management requires withholding or permanent discontinuation based on severity, and corticosteroid administration as per standard guidelines. - Infusion-related reactions: Grade 1 or 2: interrupt or slow infusion; Grade 3 or 4: permanently discontinue. - No contraindications are listed in the label.

Penpulimab-kcqx provides a new PD-1 inhibitor option for non-keratinizing nasopharyngeal carcinoma, both in the first-line setting combined with platinum-based chemotherapy and as a later-line single agent. It is one of the few immunotherapies specifically approved for this disease, offering an alternative for patients who progress on platinum-based regimens. The recommended maximum treatment duration of 24 months may guide long-term management. Clinicians should monitor for immune-related adverse events and manage according to label recommendations.